MedTrace Logo

Using e-Nose Technology to Identify Early Lung Cancer

NCT04734145 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 119

Last updated 2026-05-06

No results posted yet for this study

Summary

The purpose of this study is to test the ability of a new technology called breathprinting, or electronic nose (e-nose), to detect early-stage lung cancer. Additionally, researchers also want to see if the e-nose technology is more effective at diagnosing lung cancer if the tumor size is larger.

Conditions

Interventions

DIAGNOSTIC_TEST

Breathprinting test

Consented, enrolled participants will undergo a breathprinting test (e-nose) during the presurgical visit and at the same facility as their presurgical or prebiopsy visit, before any attempt is made to obtain cytohistological diagnosis of the pulmonary nodule.

Sponsors & Collaborators

Principal Investigators

  • Gaetano Rocco, MD · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
21 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-25
Primary Completion
2027-01-25
Completion
2027-01-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04734145 on ClinicalTrials.gov